CURRICULUM VITAE

PERSONAL DATA

Barbara Anne Pickut M.D., M.P.H.
Born Canada, Kitchener, Ontario /

Neurologist, Neurorevalidation physician

UniversityHospitalAntwerp (UZA), Belgium

Guest Professor

-Artesis College of Health Sciences – Neuroanatomy - Artesis

Hogeschool/University of Antwerp, Belgium

- College of Sociology and Law – Neurology & Mindfulness

Utrecht, The Netherlands

Addresses:

UniversityHospitalAntwerp (UZA)

Department of Neurology

Wilrijkstraat 10

2650 Edegem, Belgium

Phone: 32-(0)3-281.52.12

ArtesisCollege of Health Sciences

Van Aertselaerstraat 31

2060 Antwerpen - Merksem

Phone: 32-(0)3-641.82.65

References: (co-) author on more than 55 published articles.

CLINICAL STUDIES AND TRIALS

# / Title / Protocol# / Protocol Date
1 / A double-blind, L-dopa plus Benserazide controlled, multicenter study of Ropinirole at a flexible oral dose of 0.25 - 8 mg three times daily for five years in the treatment of early Parkinsonian patients not treated with L-dopa. / 101468/056 / March-92
2 / A double-blind, Bromocriptine controlled, multicenter study of Ropinirole at a flexible oral dose of 0.25 - 8 mg three times daily for six months in the treatment of Parkinsonian patients not optimally controlled on L-dopa (DCI).
A double-blind, Bromocriptine controlled, multicenter study of Ropinirole at a flexible oral dose for six months extension in the treatment of Parkinsonian patients not optimally controlled on L-dopa (DCI). / 101468/043 // 101468/050 / April-92
3 / Double-blind, placebo-controlled, parallel-group comparison to assess the safety, tolerance and efficacy of Pramipexole in early Parkinson’s disease (Part I) and to assess long term safety with open-label Pramipexole (Part II) / M/2730/0001 / January-93
4 / A European double-blind, placebo-controlled, parallel-group comparison to assess the safety, tolerance and efficacy of Pramipexole in early Parkinson’s disease (part I) and to assess long term safety with open-label Pramipexole (Part II) / M/2730/0005 // M/2730/0006 / June-93
5 / Study of Pergolide in the treatment of old Parkinson patients. / B4G-BX-S001 / October-99
6 / Multinational, multicenter, randomized, double-blind, double-dummy, parallel group study comparing TV-1203/ Carbidopa dispersible tablets with Levodopa/Carbidopa tablets in advanced Parkinson’s disease (PD) patients with motor fluctuations. RONDO Study. / TV-1203/116 / May-00
7 / A double blind, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of BTS 74 398 in patients with recently diagnosed Parkinson’s disease (PD) who are not being treated with any medication (early untreated PD patients). / BTSPD-003 / October-00
8 / A multinational, multicenter, open label study to evaluate the safety and tolerability of TV-1203/carbidopa dispersible tablets in advanced Parkinson’s disease (PD) patients with motor fluctuations treated with chronic Levodopa/DDI therapy. (RONDO extension) / TV-1203/118 / November-00
9 / Functional Improvement of Parkinsonian patients by Optimalizing Pergolide (FIPOP). An observational program. / B4G-UT-LCDN // FIPOP / March-01
10 / A phase II, double-blind, placebo-controlled randomized study comparing the efficacy, safety and tolerability of Sumanirole versus placebo or Ropinirole, as an adjuvant to Levodopa, in patients with advanced Parkinson’s disease. / 666E-CNS-0075-0022 / August-01
11 / A multicenter, multinational, phase III, randomized, double-blind, double-dummy, 3-arm parallel group, placebo- and Ropinirole-controlled trial of the efficacy and safety of the Rotigotine CDS patch in subjects with early stage idiopathic Parkinson’s disease (Part I), and an open-label extension to assess the safety of long-term treatment of Rotigotine CDS (Part II). / SP513 / August-01
12 / An open-label, long-term, flexible-dose study of safety, tolerability and therapeutic response of PNU-95666E in patients with Parkinson’s disease. / 666E-CNS-0075-0019 / May-00
13 / A phase III, multi-center, randomized, double-blind, placebo-controlled, fixed dose response study comparing the efficacy and safety of Sumanirole versus placebo in patients with early Parkinson’s Disease. / DA2APD-0075-031 / May-02
14 / A 24-week prospective, randomized, multicenter, double-blind, placebo-controlled, parallel group study of the efficacy, tolerability and safety of 3-12 mg/day of Exelon® (Rivastigmine) capsules in patients with Parkinson’s disease dementia. / CENA713B2311 / June-02
15 / An open-label, 24-week extension to a 24-week prospective, randomized, multicenter, double-blind, placebo-controlled, parallel-group study of the efficacy, tolerability and safety of 3-12 mg/day of Exelon® (Rivastigmine) capsules in patients with Parkinson’s Disease Dementia. / CENA713B2311E1 / December-02
16 / A randomized, double-blind, three period, cross-over study of Ropinirole CR and Ropinirole IR Monotherapy in subjects with early phase Parkinson’s disease. / 101468/168 / February-03
17 / A phase III, randomized, double blind, placebo-controlled, parallel group study of six months treatment with Ropinirole CR as adjunctive therapy in patients with phase Parkinson’s disease who are not optimally controlled on L-dopa. / SKYE-101468/169 / March-03
18 / A 24-week, multicenter, randomized, double-blind, placebo-controlled study of the efficacy, tolerability and safety of Donepezil (Aricept) in Parkinson’s disease patients with dementia. / E2020-E044-316 / December-02
19 / An open-label extension study with REQUIP (Ropinirole) CR for subjects from studies 101468/165, 101468/168 and 101468/169. / 101468/248 / September-03
20 / Feasibility study on the characteristics of Parkinson’s disease symptoms for the planned phase III studies with Sarizotan (EMR 62 225). / / / February-04
21 / A 52-week multicenter, open label extension of the safety, tolerability and efficacy of Donepezil (Aricept®) in Parkinson’s disease patients with dementia. / E2020-E044-318 / October-02
22 / A long term, double-blind, randomized, parallel-group, Carbidopa/Levodopa controlled, multi-center study to evaluate the effect of STALEVO TM in patients with Parkinson's disease who require initiation of Levodopa therapy. / CELC200A2401/2939107 / May-04
23 / A double-blind, placebo controlled, multicenter, multinational phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson’s disease suffering from treatment associated dyskinesias. PADDY-2 / EMR 62225-019 / July-04
24 / An open-label, multicenter, multinational phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson’s disease suffering from treatment-associated dyskinesias. PADDY-O / EMR 6225-030 / February-05
25 / Identificatie van nieuwe genen en risicofactoren voor de ziekte van Parkinson. / 41597 / May-05
26 / Ontwikkeling en evaluatie van een interprofessioneel valpreventieprogramma voor Parkinson-patiënten. / / / May-05
27 / Observational study to determine the incidence of new-onset cardiac valvulopathy in patients treated with Pergolide as second-line therapy for Parkinson’s disease. / B4G-MC-B001 / June-05
28 / Long-term observation study of all patients treated with Duodopa® for advanced Parkinson’s disease in Belgium. / S187.4.002 / May-07
29 / A phase III, double-blind, placebo-controlled, randomized trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of Safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of Levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an Anticholinergics and/or Amantadine. Safinamide in IPD with motor fluctuations, as add-on to Levodopa: SETTLE. / 27919 / June-07
30 / A 76-week, prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD). / CENA713B2315 / August-07
31 / A cognitive training program in Parkinson’s Disease based on principles of brain plasticity. / / / March-09
32 / Open-label trial to determine the long-term safety of Safinamide in Parkinson’s disease patients. / 28850 / July-09
33 / Identificatie van genen en genetische risicofactoren voor de ziekte van Parkinson. / / / November-09

SOCIETES

  • Member of the American Association of Public Health (1982)
  • Member of the American Association for World Health (1983)
  • Dutch Belgian Experimental and Clinical Neurochemistry Association (1992)
  • Member Flemish Neurological Association (Vlaamse Vereniging van Zenuwartsen) (1995)
  • Flemish Workgroup Movement Disorders, officially recognized by the
    Movement Disorders Society, 2010 (2006)
  • Member Movement Disorder Society (2007)

ADVISORY BOARDS

Participation in / member of the following Advisory Boards for:

  • Boehringer Ingelheim
  • GSK (GlaxoSmithKline)
  • Novartis
  • Solvay Pharmaceuticals
  • UCB

CV Barbara A. PickutPage 1/5